-DOCSTART- -X- O
ABSTRACT -X- _ O
: -X- _ O
Emerging -X- _ O
viral -X- _ O
pathogens -X- _ O
include -X- _ O
newly -X- _ O
discovered -X- _ O
viruses -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
previously -X- _ O
known -X- _ O
viruses -X- _ O
that -X- _ O
are -X- _ O
either -X- _ O
increasing -X- _ O
, -X- _ O
or -X- _ O
threatening -X- _ O
to -X- _ O
increase -X- _ O
in -X- _ O
incidence. -X- _ O
While -X- _ O
often -X- _ O
first -X- _ O
identified -X- _ O
in -X- _ O
the -X- _ O
general -X- _ O
population -X- _ O
, -X- _ O
they -X- _ O
may -X- _ O
affect -X- _ O
transplant -X- _ B-Patient
recipients -X- _ I-Patient
, -X- _ O
in -X- _ O
whom -X- _ O
their -X- _ O
manifestations -X- _ O
may -X- _ O
be -X- _ O
atypical -X- _ O
or -X- _ O
more -X- _ O
severe. -X- _ O
Enhanced -X- _ O
molecular -X- _ O
methods -X- _ O
have -X- _ O
increased -X- _ O
the -X- _ O
rate -X- _ O
of -X- _ O
viral -X- _ O
discovery -X- _ O
but -X- _ O
have -X- _ O
not -X- _ O
overcome -X- _ O
the -X- _ O
problem -X- _ O
of -X- _ O
demonstrating -X- _ O
pathogenicity. -X- _ O
At -X- _ O
the -X- _ O
same -X- _ O
time -X- _ O
, -X- _ O
improved -X- _ O
clinical -X- _ O
diagnostic -X- _ O
methods -X- _ O
have -X- _ O
increased -X- _ O
the -X- _ O
detection -X- _ O
of -X- _ O
reemerging -X- _ O
viruses -X- _ O
in -X- _ O
immunocompromised -X- _ O
patients. -X- _ O
In -X- _ O
this -X- _ O
review -X- _ O
, -X- _ O
we -X- _ O
first -X- _ O
discuss -X- _ O
viral -X- _ O
diagnostics -X- _ O
and -X- _ O
the -X- _ O
developing -X- _ O
field -X- _ B-Outcome
of -X- _ I-Outcome
viral -X- _ I-Outcome
discovery -X- _ I-Outcome
and -X- _ I-Outcome
then -X- _ I-Outcome
focus -X- _ I-Outcome
on -X- _ I-Outcome
rare -X- _ I-Outcome
and -X- _ I-Outcome
emerging -X- _ I-Outcome
viruses -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
transplant -X- _ I-Outcome
population -X- _ I-Outcome
: -X- _ I-Outcome
human -X- _ I-Outcome
T-cell -X- _ I-Outcome
leukemia -X- _ I-Outcome
virus -X- _ I-Outcome
type -X- _ I-Outcome
1 -X- _ I-Outcome
; -X- _ I-Outcome
hepatitis -X- _ I-Outcome
E -X- _ I-Outcome
virus -X- _ I-Outcome
; -X- _ I-Outcome
bocavirus -X- _ I-Outcome
; -X- _ I-Outcome
KI -X- _ I-Outcome
and -X- _ I-Outcome
WU -X- _ I-Outcome
polyomaviruses -X- _ I-Outcome
; -X- _ I-Outcome
coronaviruses -X- _ I-Outcome
HKU1 -X- _ I-Outcome
and -X- _ I-Outcome
NL63 -X- _ I-Outcome
; -X- _ I-Outcome
influenza -X- _ I-Outcome
, -X- _ I-Outcome
H1N1 -X- _ I-Outcome
; -X- _ I-Outcome
measles -X- _ I-Outcome
; -X- _ I-Outcome
dengue -X- _ I-Outcome
; -X- _ I-Outcome
rabies -X- _ I-Outcome
; -X- _ I-Outcome
and -X- _ I-Outcome
lymphocytic -X- _ I-Outcome
choriomeningitis -X- _ I-Outcome
virus. -X- _ I-Outcome
Detection -X- _ O
and -X- _ O
reporting -X- _ O
of -X- _ O
such -X- _ O
rare -X- _ O
pathogens -X- _ O
in -X- _ O
transplant -X- _ O
recipients -X- _ O
is -X- _ O
critical -X- _ O
to -X- _ O
patient -X- _ O
care -X- _ O
and -X- _ O
improving -X- _ O
our -X- _ O
understanding -X- _ O
of -X- _ O
posttransplant -X- _ O
infections -X- _ O
. -X- _ O

